Efficacy and safety of emapalumab in macrophage activation syndrome
2023/03/31 by Fabrizio De Benedetti, Alexei A. Grom, Alexei A Grom +17 · 27 citations
Medicine · #Autoimmune and Inflammatory Disorders Research #Acute Lymphoblastic Leukemia research #Hemophilia Treatment and Research
paper · pdf · doi:10.1136/ard-2022-223739
Abstract
OBJECTIVES: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD). The objective of this study was to confirm the adequacy of an emapalumab dosing regimen in relation to interferon-γ (IFNγ) activity by assessing efficacy and safety. The efficacy outcome was MAS remission by week 8, based on clinical and laboratory criteria. METHODS: We studied emapalumab, a human anti-IFNγ antibody, administered with background glucocorticoids, in a prospective single-arm trial involving patients who had MAS secondary to sJIA or AOSD and had previously failed high-dose glucocorticoids, with or without anakinra and/or ciclosporin. The study foresaw 4-week treatment that could be shortened or prolonged based on investigator's assessment of response. Patients entered a long-term (12 months) follow-up study. RESULTS: Fourteen patients received emapalumab. All patients completed the trial, entered the long-term follow-up and were alive at the end of follow-up. The investigated dosing regimen, based on an initial loading dose followed by maintenance doses, was appropriate, as shown by rapid neutralisation of IFNγ activity, demonstrated by a prompt decrease in serum C-X-C motif chemokine ligand 9 (CXCL9) levels. By week 8, MAS remission was achieved in 13 of the 14 patients at a median time of 25 days. Viral infections and positive viral tests were observed. CONCLUSIONS: Neutralisation of IFNγ with emapalumab was efficacious in inducing remission of MAS secondary to sJIA or AOSD in patients who had failed high-dose glucocorticoids. Screening for viral infections should be performed, particularly for cytomegalovirus. TRIAL REGISTRATION NUMBER: NCT02069899 and NCT03311854.
Cited by
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
- Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death
- IFN-α induced systemic lupus erythematosus complicated with hemophagocytic lymphohistiocytosis: a case report and literature review. [europepmc]
- Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease. [europepmc]
- Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. [europepmc]
- Systemic juvenile idiopathic arthritis: The Great Ormond Street Hospital experience (2005-2021). [europepmc]
- Performance of interferon-gamma levels may lead to earlier diagnosing macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. [europepmc]
- Inpatient recognition and management of HLH. [europepmc]
- Biological and clinical roles of IL-18 in inflammatory diseases. [europepmc]
- Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia. [europepmc]
- Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne. [europepmc]
- Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. [europepmc]
- Interferon- γ and infectious diseases: Lessons and prospects. [europepmc]
- One gene to rule them all - clinical perspectives of a potent suppressor of cytokine signaling - SOCS1. [europepmc]
- Heterogeneity of macrophage activation syndrome and treatment progression. [europepmc]
- Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. [europepmc]
- The next frontier in immunotherapy: potential and challenges of CAR-macrophages. [europepmc]
- Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. [europepmc]
- Systemic T-cell activation and IFN-γ activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-γ-directed therapies. [europepmc]
- Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease. [europepmc]
- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. [europepmc]
- Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. [europepmc]
- Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms. [europepmc]
- Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). [europepmc]
- Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH). [europepmc]
- Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. [europepmc]
- Macrophage activation syndrome-associated adult onset Still disease treatment: a scoping review of case reports and case series. [europepmc]
Related